Astellas, Dana-Farber form cancer drug discovery pact; German researchers find antibiotic alternative;

> Japanese company Astellas has inked a $1.2 billion pact with the Dana-Farber Cancer Institute for a three-year collaboration to develop small molecule inhibitors to treat cancer. More

> Researchers from the University of Cincinnati have found that an antibody common in mice and previously thought to offer poor assistance in fighting against infection may actually help prevent serious self-inflicted forms of kidney disease. More

> Scientists from the University of Bern have developed a novel, nonantibiotic agent that could treat severe bacterial infections. Abstract

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.